Clinical Trials Browser

NCT04840602 2026-06-05

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Phase 2 Recruiting

92 enrolled

Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT07231952 2026-06-03

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Phase 2 Recruiting

40 enrolled

Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT04542824 2026-06-02

EPCORE™ NHL-3

Phase 1/2 Active not recruiting

78 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT05100862 2026-05-27

MAHOGANY

Phase 3 Recruiting

780 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT07583810 2026-05-15

Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma

Phase 2 Not yet recruiting

35 enrolled

Lymphoid

Lymphoma, Lymphoma, B-Cell, Marginal Zone

NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Phase 2/3 Active not recruiting

422 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT03474744 2026-05-06

Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

Phase 2 Active not recruiting

36 enrolled

Lymphoid

Neoplasms, Lymphoma, B-Cell, Marginal Zone

NCT06149286 2026-05-06

OLYMPIA-5

Phase 3 Recruiting

470 enrolled

Lymphoid

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT02433795 2026-04-22

Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)

Phase 2 Completed

27 enrolled 12 charts

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT04433156 2026-04-09

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

Phase 2 Completed

26 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT03697512 2026-04-08

MALIBU

Phase 2 Active not recruiting

175 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT01479842 2026-03-23

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

Phase 1 Active not recruiting

48 enrolled

Lymphoid

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05025800 2026-03-20

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Phase 1/2 Active not recruiting

47 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Composite Lymphoma